The purpose of this study is to examine whether the duration of treatment with phenobarbital has an impact on neurodevelopmental and epilepsy outcomes, as well as parent and family well-being, after neonatal seizures.
Neonates <44 weeks corrected age at seizure onset
Seizures due to acute brain injury
Parent(s) who are English or Spanish literate (with assistance of interpreter)
Neonates at risk for adverse outcome independent of seizures and underlying brain injury
Neonates with mild, temporary causes for seizures
Newborns with neonatal-onset epilepsy syndromes
Neonates who do not survive the initial hospital admission
Neonates will not be excluded based on race, ethnicity, gender or gestational age
December 4, 2020
Renée Shellhaas, MD
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: